ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non-muscle-invasive bladder cancer Meeting Abstract

sustainable development goals

publication date

  • June 1, 2025

webpage

published in

start page

  • TPS4632

end page

  • TPS4632

volume

  • 43

issue

  • 16_SUPPL